Meeting
2023 ASCO Annual Meeting
Are we ready for biomarker driven, radiation dose–adaptable de-escalation studies for HPV+ oropharyngeal cancer?
Authors
Krzysztof Misiukiewicz
Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
Krzysztof Misiukiewicz , Leslie Worona , Emily J Ramos , Richard Lorne Bakst , Kunal K. Sindhu , Wiliam J Westra , Scott Roof , Marshall R. Posner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6084)
DOI
10.1200/JCO.2023.41.16_suppl.6084
Abstract #
6084
Poster Bd #
76
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The Quarterback trials: A phase 2 series of sequential studies of induction chemotherapy followed by reduced dose chemoradiation for human papillomavirus positive oropharynx cancer.
First Author: Marshall R. Posner
Poster
2023 ASCO Annual Meeting
Randomized phase I/II trial of TheraT vectors expressing HPV16 specific antigens with neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) or risk/response stratified chemoradiotherapy (CRT) for locoregional HPV16+ oropharyngeal cancer (OPC).
First Author: Ari Rosenberg
Poster
2022 ASCO Annual Meeting
Swallowing and quality-of-life outcomes of response adaptive de-escalated therapy following nivolumab-based induction for HPV+ oropharyngeal cancer.
First Author: Ari Rosenberg
Poster
2021 ASCO Annual Meeting
Survival (OS) and progression-free survival (PFS) results after induction chemotherapy (IC) followed by de-escalated chemoradiotherapy (RDCRT) for locally advanced (LA) HPV positive oropharynx cancer (HPVOPC.
First Author: Marshall R. Posner